Navigation Links
Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
Date:1/7/2008

FRAZER, Pa., Jan. 7 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the presentation slides that will be used by the company at the JPMorgan Healthcare Conference are now available on the "Investor Information" section of the company's website at http://www.cephalon.com. On Tuesday, January 8, 2008, Frank Baldino, Jr., Ph.D., Chairman and CEO, will deliver a one hour presentation at the Conference beginning at 2:00 p.m. Pacific Time (5 p.m. Eastern Time).

Live Web Cast and Archived Replay

Members of the financial and investment community, the media and other interested parties can access a live web cast of the presentation through the Investor Information section of the company's website http://www.cephalon.com. Following the live presentation, a replay of the presentation will be available for two weeks on the Company's website.

About Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
2. Cephalon Submits Supplemental New Drug Application for FENTORA
3. Cephalon Announces Strong Third Quarter Financial Results
4. Cephalon Quarterly Conference Call Invitation
5. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
6. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
7. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
11. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 2016 , ... The Ankle Plating System 3 and Small ... fractures of the distal tibia and fibula. This system marks Acumed's continued commitment ... is composed of seven plate families that span the lateral, medial, and posterior ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... (RFI) issued by the Office of the National Coordinator for Health IT (ONC) ... determines if clinically relevant data were available when and where it was needed. ...
(Date:5/25/2016)... CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... in healthcare information exchange, today announced that Charles W. Stellar has been named by ... WEDI’s interim CEO since January 2016. As an executive leader with more than 35 ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Drug Administration (FDA) has granted the company’s orphan drug designation request covering BHV-4157 ... drug designation granted by the FDA. , Spinocerebellar ataxia is a rare, ...
Breaking Biology Technology:
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):